Placebo for olaparib: Clinical Trials

2 active not recruiting, 1 completed. 2 Phase 3, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	2	Active not recruiting 1, Completed 1
Phase 2	1	Active not recruiting 1

Follow Placebo for olaparib: new trials by email Literature Review of Placebo for olaparib trials Research Report on Placebo for olaparib

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) Pembrolizumab, Olaparib, Placebo for olaparib - Lung Neoplasms, Carcinoma, Non-Small-Cell Lung	Phase 3	Active not recruiting	Merck Sharp & Dohme LLC	870	2020-07-06	2026-05-15
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) Durvalumab, Placebo for Olaparib, Olaparib - Non-small Cell Lung Cancer NSCLC	Phase 2	Active not recruiting	AstraZeneca	401	2018-12-21	2026-09-11
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) Pembrolizumab, Placebo for pembrolizumab, Carboplatin - Ovarian Cancer, Fallopian Tube Cancer	Phase 3	Completed	Merck Sharp & Dohme LLC	1367	2018-12-18	2026-08-19

Conditions studied

Parkinson Disease 4, Autosomal Dominant Lewy Body (2)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Fallopian Tube Neoplasms (1)  ·  Lung Neoplasms (1)  ·  Ovarian Neoplasms (1)  ·  Peritoneal Neoplasms (1)

Sponsors

Merck Sharp & Dohme LLC (2)  ·  AstraZeneca (1)

Countries

Hungary (3)  ·  Japan (3)  ·  Poland (3)  ·  Russia (3)  ·  South Korea (3)  ·  Ukraine (3)  ·  United States (3)  ·  Belgium (2)  ·  Canada (2)  ·  Chile (2)  ·  Czechia (2)  ·  France (2)  ·  Germany (2)  ·  Italy (2)  ·  Mexico (2)

Top investigators

Myung-Ju Ahn, MD (1)

Results publications

PMID 35618629, PMID 37390980, PMID 42705254

NIH funding

2018 (2), 2019 (1), 2023 (1)